Intra-brand competition in the pharmaceutical sector : comments to the CJEU Advocate General Opinion
On 13 January 2022, CJEU Advocate General Szpunar delivered his opinion in cases related to the practical necessity to re-box versus re-label parallel imported pharmaceuticals, following the implementation of the Falsified Medicines Directive.
AG Szpunar’s opinion would set the precedent for a new doctrine on intra-brand competition in the EU’s Internal Market writes our Secretary General, Kasper Ernest.
See the full analysis published on European Competition Law Review.
Affordable Medicines Europe
Copyright – AffordableMedicines- created by Incendiary